Brazil authorizes Butanvac vaccine for volunteers in clinical trial
BRASILIA, July 7 (Reuters) – Brazilian health regulator Anvisa on Wednesday gave the go-ahead for the Butanvac COVID-19 vaccine developed by Sao Paulo’s Butantan Institute biomedical center to be used on volunteers in clinical trials.
Anvisa in a statement said the vaccine will be applied in two doses, 28 days apart. Phase I of Butanvac’s clinical trial will involve 400 volunteers, and the first two phases are expected to involve 6,000 volunteers in total.
By Jamie McGeever via Reuters